- Home
- GSIW vs IMRN Comparison
GSIW vs IMRN Comparison
Compare GSIW & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- IMRN
- Stock Information
- Founded
- GSIW 2016
- IMRN 1994
- Country
- GSIW Hong Kong
- IMRN Australia
- Employees
- GSIW N/A
- IMRN N/A
- Industry
- GSIW
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- IMRN Health Care
- Exchange
- GSIW Nasdaq
- IMRN Nasdaq
- Market Cap
- GSIW 8.3M
- IMRN 9.2M
- IPO Year
- GSIW 2023
- IMRN N/A
- Fundamental
- Price
- GSIW $1.15
- IMRN $1.70
- Analyst Decision
- GSIW
- IMRN Strong Buy
- Analyst Count
- GSIW 0
- IMRN 1
- Target Price
- GSIW N/A
- IMRN $5.00
- AVG Volume (30 Days)
- GSIW 2.1M
- IMRN 53.5K
- Earning Date
- GSIW 12-31-2024
- IMRN 06-17-2025
- Dividend Yield
- GSIW N/A
- IMRN N/A
- EPS Growth
- GSIW N/A
- IMRN N/A
- EPS
- GSIW N/A
- IMRN N/A
- Revenue
- GSIW $1,313,795.00
- IMRN $4,048,286.00
- Revenue This Year
- GSIW N/A
- IMRN N/A
- Revenue Next Year
- GSIW N/A
- IMRN N/A
- P/E Ratio
- GSIW N/A
- IMRN N/A
- Revenue Growth
- GSIW N/A
- IMRN 82.90
- 52 Week Low
- GSIW $0.35
- IMRN $1.50
- 52 Week High
- GSIW $12.30
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- GSIW 78.55
- IMRN 43.37
- Support Level
- GSIW $0.73
- IMRN $1.69
- Resistance Level
- GSIW $0.77
- IMRN $1.89
- Average True Range (ATR)
- GSIW 0.10
- IMRN 0.17
- MACD
- GSIW 0.03
- IMRN -0.01
- Stochastic Oscillator
- GSIW 86.84
- IMRN 34.06
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.